MLNM phase III-Very encouraging data.
Encouraging, yes, but actually Phase I and pre-clinical:
Session Info. : Simultaneous Session: Molecular Target Based Therapy for Multiple Myeloma (10:30 AM-12:30 PM), Monday, December 09, 2002
[388] Phase I Study of the Proteasome Inhibitor Bortezomib (PS-341, velcade™) in Combination
[5137] The Proteasome Inhibitor PS-341 Is More Cytotoxic in Myeloma Cells Adhered to Fibronectin.
Terry H. Landowski, Julian Adams, William S. Dalton. Arizona Cancer Center, University of Arizona, Tucson, AZ, USA; Millenium Pharm. Inc, Cambridge, MA, USA; H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
[snip]
The proteasome inhibitor, PS-341, is a dipeptidyl boronic acid that has shown activity in clinical trials in patients with multiple myeloma. Using oligonucleotide microarray analysis, we have examined the differential gene expression profile of 8226 multiple myeloma cells treated with PS-341 in contact with the extracellular matrix (ECM) component, fibronectin compared to cells treated in suspension culture. Microarray analysis demonstrated . . . |
